Previous 10 | Next 10 |
HAMPTON, N.J., July 31, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2019 financial results on Wednesday, August 7, 2019 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to...
Note: This article was first revealed to subscribers to my exclusive marketplace, The Formula , in February when shares of Blueprint were trading < $80. Preface Documents: 10-Q | Company Slides Shares: 48,853,933 | PPS: $100 | Market Cap: $4.8B | Enterprise Value...
HAMPTON, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the appointment of Diane C. Young, M.D., as Senior Vice President, Chief Medical Officer, effective July 8, 2019. Over the span of a 30 year career, Dr. Young, a medical oncologist, has...
Genocea Biosciences (NASDAQ: GNCA ) +94% on positive GEN-009 data in cancer patients. More news on: Genocea Biosciences, Inc., Cypress Semiconductor Corporation, Outlook Therapeutics, Inc., Stocks on the move, Read more ...
--Evaluation of biomarkers for patient selection to be incorporated into expanded development program-- HAMPTON, N.J., June 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented results from the CDX-3379 clinical program at the 2019 American Soc...
Celldex (NASDAQ: CLDX ): Q1 GAAP EPS of -$1.40 misses by $0.26 . More news on: Celldex Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HAMPTON, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019. “Celldex presented positive data across multiple programs at AACR in April, including from our promi...
Energy Focus (NASDAQ: EFOI ) -52% on Q4 earnings . More news on: Energy Focus, Inc., Evoke Pharma, Inc., Apyx Medical Corporation, Stocks on the move, Read more ...
--CDX-1140 has achieved good systemic exposure without reaching a maximum tolerated dose to date-- --Addition of dendritic cell growth factor CDX-301 enhances cytokine response without additive toxicity at dose levels tested to date-- --Tumor specific expansion cohorts planned-- ...
HAMPTON, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented promising data from the Company’s growing bispecific and TAM (Tyro3, Axl, MerTK) receptor programs during poster sessions today at the American Association for Cancer Research (AACR) ...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...